Number of eligible patients: CDEC discussed the uncertainty in the number of patients with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some patients who are categorized as owning moderate or reasonable ailment could have a significant bleeding phenotype, https://hemgenix49371.techionblog.com/35812637/a-review-of-hemgenix